An Biping announced that from July to September 2026, the company and its subsidiaries obtained 19 domestic medical device registration certificates, 3 intellectual property qualifications, and 1 overseas qualification. Among them, 19 medical device registration certificates are all Class I, covering categories such as immunohistochemical antibody reagents and fluorescence in situ hybrid probe reagents; 3 intellectual property rights include 1 invention patent and 2 utility model patents; the overseas qualification is CE registration for sample preservation solutions. Obtaining the above qualifications is conducive to enriching product types, improving the intellectual property system, expanding overseas scenarios, and enhancing core competitiveness. The actual sales situation of related products is uncertain, so investors are kindly requested to pay attention to investment risks.

An Biping announced that from July to September 2026, the company and its subsidiaries obtained 19 domestic medical device registration certificates, 3 intellectual property qualifications, and 1 overseas qualification. Among them, 19 medical device registration certificates are all Class I, covering categories such as immunohistochemical antibody reagents and fluorescence in situ hybrid probe reagents; 3 intellectual property rights include 1 invention patent and 2 utility model patents; the overseas qualification is CE registration for sample preservation solutions. Obtaining the above qualifications is conducive to enriching product types, improving the intellectual property system, expanding overseas scenarios, and enhancing core competitiveness. The actual sales situation of related products is uncertain, so investors are kindly requested to pay attention to investment risks.